StocksMedium•16 November 2026•
1 min read
Seawolf Therapeutics Launches with $100M Funding and $1.2B Sanofi Deal
Key Facts
1Seawolf Therapeutics launched with $100 million in funding to develop redosable DNA medicines.
2The company secured a research and licensing deal with Sanofi worth up to $1.2 billion.
3Funding participants included Novartis Venture Fund, Eli Lilly, and CRISPR Therapeutics.
Seawolf Therapeutics launched with $100 million in funding to develop redosable DNA medicines. BioSpace reported that the company secured a research and licensing deal with Sanofi worth up to $1.2 billion, focusing on therapies for bleeding disorders and leveraging the Trident delivery platform for multi-target research.
Funding participants for Seawolf Therapeutics included major industry players such as Novartis Venture Fund, Eli Lilly, and CRISPR Therapeutics. Following the announcement, Sanofi closed at $48.37 on November 13, 2026, while Novartis closed at $160.50 and Eli Lilly closed at $1,443.50 on the same date. CRISPR Therapeutics recorded a close of $42.24 on November 13, 2026.